News

Keep you updated

with the latest info of XtalPi

XtalPi Partners with A*STAR under MARVEL-AI to Advance AI-Driven Materials Innovation
XtalPi Nominates Its First siRNA Preclinical Candidate for IgA Nephropathy Nine Months After Program Initiation
Ailux Appoints Lloyd S. Miller, M.D., Ph.D., as Chief Medical Officer
XtalPi Open-Sources the First AI Model for Chemical Reaction Yield Quantification
Ailux Presents New Preclinical Data Supporting its Long-Acting IL-4Rα Antibody and Expanding its Bispecific Applications at EADV 2026
XtalPi Debuts Kodexia™, the World’s First Closed-Loop siRNA Platform Combining Generative AI with First-Principles Modeling
XtalPi Advances Hair Loss Drug Program into IND-Enabling Studies
XtalPi and Fangda Carbon Deploy Predictive AI to Optimize Cost and Material Efficiency in Graphite Electrode Manufacturing
XtalPi Submits U.S. FDA IND Application for KQTD-126, a Potential First-in-Class, Gut-Restricted Pan-TRK Inhibitor for Chronic Intestinal Pain
XtalPi AI Enables Seven-Month PCC Nomination for Viva-Thera’s MPER-Targeting HIV-1 Program
XtalPi-Enabled META Pharmaceuticals’ MP-5342 Advances Toward IND, with Key Preclinical Studies Completed
XtalPi Announces Strategic Partnership with a Leading Biopharma to Develop Oral Small Molecule Therapeutics for a GPCR Target

Search XtalPi

Integrating Multimodal AI with Encoded Medicinal Knowledge and Physics Simulations: A Unified Platform for Accelerated Drug Discovery from Patent Analysis to Potency Validation
AI-Predicted Full-Spectrum UV Correction Factors: An Analyte-Standard-Free Framework for Reaction Yield Quantification
SureRoute: Toward a Hallucination-Free Self-Improving Platform for Retrosynthesis

XtalPi Newsletter